Stephane Litschig

CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding

Stephane Litschig, F. Gasparini, D Rueegg et al. · Molecular Pharmacology · 1999 · 342 citations

The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors

Adriana Pagano, Doris Rüegg, Stephane Litschig et al. · Journal of Biological Chemistry · 2000 · 267 citations · Full text

Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib

R. Lehmann, Marek Brzosko, Petr Kopsa et al. · Current Medical Research and Opinion · 2005 · 73 citations

Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout

R. Willburger, Eduardo Mysler, J. Derbot et al. · Lara D. Veeken · 2007 · 61 citations · Full text